

CMP: ₹ 1221

Target: ₹ 1340 (10%)

Target Period: 12 months

February 7, 2023

Distribution expansion, new products driving volumes

About the stock Varun Beverage (VBL) is one of the largest franchisees of PepsiCo in the world. The company produces & distributes carbonated drinks, juices & packaged drinking water in six countries including India. Some of the PepsiCo brands produced by VBL include Pepsi, Diet Pepsi, Seven-Up, Mirinda, Mountain Dew, Nimbooz, Sting, Slice, Tropicana, Aquafina among others.

• The company has operations in India (except Andhra Pradesh, J&K & Ladakh), Sri Lanka, Nepal, Morocco, Zambia and Zimbabwe

Q4CY22 Results: Varun Beverages witnessed strong volume growth of 17.8%.

- Sales were up 27.7% YoY led by strong volume & superior product mix
- EBITDA was at ₹ 307.5 crore, up 48.1% YoY, with margins at 13.9%
- Consequently, PAT was at ₹ 81.5 crore, up 2.5x

What should investors do? Varun Beverage's share price has given 6.3x return (from ₹ 195 in February 2018 to ₹ 1221 in February 2023).

- We estimate 10% volume CAGR & sustainable operating margins above 21%. This would lead to earning CAGR of 12.1% in CY22-24E
- We maintain our HOLD recommendation on the stock

Target Price and Valuation: We value the stock at ₹ 1340, valuing the business at 45x CY24 PE.

Key triggers for future price performance:

- VBL has seen 15% organic volume growth in the last three years led by distribution expansion in underpenetrated territories and new launches (Sting, milk based beverages, etc). We expect volume growth to moderate to 10% level in the next two years
- It is setting up two new plants in Rajasthan & Madhya Pradesh along with brownfield expansion in six other plants, which would enhance its capacity by 20-25%. This would entail capex of ₹ 1500 crore
- Newer brands 'Sting' & milk-based beverages are growing at a faster pace, supporting overall volume growth. Energy drink 'Sting' is contributing 9.6% to overall volumes in CY22

Alternate Stock Idea: We like Tata Consumer Products in our FMCG coverage.

- Strong innovation & premiumisation strategy in salt, tea, Sampann & Soulful in India market expected to drive sales and margins
- We value the stock at ₹ 950 on ascribing 52x FY25 earnings multiple



HOLD

Particulars	
Particulars (₹ crore)	Amount
Market Capitalization	79,300.1
Total Debt (CY22)	3,718.4
Cash & Investments (CY22)	307.5
EV	82,710.9
52 week H/L (₹)	1432 / 557
Equity capital	288.7
Face value	10.0

Shareho	lding pa	ttern		
(in %)	Mar-22	Jun-22	Sep-22	Dec-22
Promoter	64.9	63.9	63.9	63.9
FII	21.0	23.9	25.0	26.5
DII	7.2	5.3	4.5	3.4
Others	6.9	6.9	6.6	6.2

Price Chart



Recent event & key risks

- VBL would increase its distribution reach to 3.5 million outlets by end of CY23
- Key Risk: (i) Possibility of softer summer product demand due to adverse weather conditions in CY23 (ii) Significant decline in PET resin prices could enhance margins positively

Research Analyst

Sanjay Manyal sanjay.manyal@icicisecurities.com

Key Financial Summa	y						
	CY20	CY21	CY22	5 Year CAGR (CY17- CY22)	CY23E	CY24E	CAGR (CY22-24E)
Net Sales	6450.1	8823.2	13173.1	26.9	14558.6	16263.8	11.1%
EBITDA	1201.9	1654.6	2788.1	27.2	3105.3	3478.2	11.7%
EBITDA Margin %	18.6	18.8	21.2		21.3	21.4	
Net Profit	362.1	746.1	1550.1	48.6	1692.2	1946.5	12.1%
Diluted EPS (₹)	5.6	11.5	23.9	15.3	26.1	30.0	12.1%
P/E	219.0	106.3	51.2		46.9	40.7	
RoNW %	10.3	18.3	30.4		26.6	25.5	
RoCE (%)	10.9	17.1	23.8		27.2	30.6	

Source: Company, ICICI Direct Research

Key takeaways of recent quarter

Q4CY22 Results: New products (Sting, Dairy products) & distribution expansion resulting in high growth...

- Revenue witnessed growth of 27.7% to ₹ 2214.2 crore led by 17.8% volume growth & 6% realisation growth during the quarter. Consolidated sales volumes and average realisation were at 132 million cases and ₹ 164 per case, respectively, in Q4CY22
- Carbonated soft drinks (CSD), juices & water account for 65%, 5% & 30% of the total volumes for the company in Q4 whereas their contribution in CY22 was 70%, 7% & 23%, respectively
- Distribution network expansion to 3 million retail outlets along with robust demand conditions due to increased mobility after two years of Covid disruption led to the strong growth in volumes throughout the year
- Energy drink 'String' witnessed stupendous growth in CY22. It contributed 16% to volumes in Q4CY22 & 9.6% in CY22. The company expects to maintain growth momentum in 'Sting' along with volume uptick in its dairy based products in CY23
- Energy drink products have been contributing 10-15% to the beverage market in emerging markets. The availability of product at lower price points in India in last five years has led to multi-fold growth
- Realisation growth of 6% was led by selective price increases and rationalisation of trade discounts. Single serve SKUs gross as well as operating margins are better than multi-serve SKUs. Given 'Sting' largely sold in smaller pack, higher growth in the brand aided realisation growth
- Varun Beverages Morocco SA (a wholly owned subsidiary of the company) started distribution & selling PepsiCo's snack products viz. "Lays, Doritos and Cheetos" in the territory of Morocco. However, it is unlikely to get manufacturing & distribution of snacks products in India from PepsiCo
- The company has started pre-stocking of raw material as well initiated brownfield capacity addition much earlier (November-December) this year as it does not want to go out of stock in any of its line in peak summer season (March-June)
- PET resin prices are generally lower in November-December. Early
 procurement of key raw materials could safeguard it from volatility in peak
 season. South & western territories (acquired in 2019) are important and
 given summer season in the south starts in February, it is important to add
 capacities earlier now
- The company expanded its distribution reach to 3.0 million outlets. It would increase its reach by 10-15% every year. Distribution network would be enhanced to 3.5 million outlets by end of 2023. Visi coolers, trucks & related capacities would be added proportionally
- Dairy product national rollout is only possible by 2024 given new dairy capacities would come on stream by end of this year. The company is enhancing its dairy product capacity by 3x. Sourcing of milk & other raw material would not be a problem for the company
- Gross margins expanded by 91 bps in Q4CY22 on account of change in product mix (high contribution of 'Sting') & softening of PET resins prices
- Employee & overhead spends were lower by 53 bps & 48 bps, respectively. This led to operating profit growth of 48.1% to ₹ 307.5 crore with operating margin expansion of 192 bps to 13.9%. Despite higher interest cost & depreciation provisioning, net profit jumped to ₹ 81.5 crore in Q4CY22 compared to ₹ 32.6 crore in the corresponding quarter

- The company would be undertaking capex of ₹ 1500 crore in CY23, which includes two greenfield plants in Rajasthan, Madhya Pradesh & brownfield expansion in six other plants in India
- Net debt for the company increased to ₹ 3409.6 crore in December 2022 compared to ₹ 3005.3 crore in December 2021 mainly due company's capex plan in CY23. The debt levels would go down in H1CY23 with repayment of debt through large operating cash flows. Hence, interest levels are likely to remain similar to CY22 numbers
- The company declared a final dividend of ₹ 1/share. Total dividend for the year is ₹ 3.5/share. Total outflow for dividend payout is ₹ 227.2 crore in CY22

arison																		
Sector / Company CMP			М Сар	M Cap Sales growth (%)		h (%)	EBITDA Margins (%) P/E(x)) RoE (%)			R	OCE (%))			
(₹)	(₹)	Rating	(₹ Cr)	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E	FY22E	FY23E	FY24E
19022	22400	Hold	190912	10.2	14.3	10.5	24.5	22.3	24.1	85.5	74.4	63.2	111.3	103.6	110.3	58.7	57.1	63.0
545	700	Buy	97880	13.9	5.9	10.6	20.7	19.6	20.7	55.3	53.1	45.3	20.8	20.5	22.2	24.9	23.9	26.1
1222	1340	Hold	79300	36.8	49.3	10.5	18.8	21.2	21.3	70.9	51.2	46.9	18.3	30.4	26.6	17.1	23.8	27.2
1465	2000	Buy	8979	23.1	14.3	21.6	17.2	17.3	18.8	30.2	26.6	21.7	6.4	7.1	8.3	6.1	6.8	8.1
	CMP (₹) 19022 545 1222	CMP TP (₹) (₹) 19022 22400 545 700 1222 1340	CMP TP (₹) (₹) Rating 19022 22400 Hold 545 700 Buy 1222 1340 Hold	CMP TP M Cap (₹) Rating (₹ Cr) 19022 22400 Hold 190912 545 700 Buy 97880 1222 1340 Hold 79300	CMP TP M Cap Sales (₹) (₹) Rating (₹ Cr) FY22E 19022 22400 Hold 190912 10.2 545 700 Buy 97880 13.9 1222 1340 Hold 79300 36.8	CMP TP M Cap Sales growth (₹) (₹) Rating (₹ Cr) FY22E FY23E 19022 22400 Hold 190912 10.2 14.3 545 700 Buy 97880 13.9 5.9 1222 1340 Hold 79300 36.8 49.3	CMP TP M Cap Sales growth (%) (₹) (₹) Rating (₹ Cr) FY22E FY23E FY24E 19022 22400 Hold 190912 10.2 14.3 10.5 545 700 Buy 97880 13.9 5.9 10.6 1222 1340 Hold 79300 36.8 49.3 10.5	CMP TP M Cap Sales growth (%) EBITDA (₹) Rating (₹ Cr) FY22E FY23E FY24E FY22E 19022 22400 Hold 190912 10.2 14.3 10.5 24.5 545 700 Buy 97880 13.9 5.9 10.6 20.7 1222 1340 Hold 79300 36.8 49.3 10.5 18.8	CMP TP M Cap Sales growth (%) EBITDA Margi (₹) Rating (₹ Cr) FY22E FY23E FY24E FY22E FY22E FY24E FY22E FY22E FY24E FY22E FY22E FY24E FY22E FY24E FY22E FY24E FY22E FY24E FY22E FY24E FY22E FY24E F	CMP TP M Cap Sales growth (%) EBITDA Margins (%) (₹) Rating (₹ Cr) FY22E FY23E FY24E FY22E FY23E FY24E FY22E FY23E FY24E FY24E FY24E FY23E FY24E FY24E<	CMP TP M Cap Sales growth (%) EBITDA Margins (%) (₹) Rating (₹ Cr) FY22E FY23E FY24E FY22E FY23E FY24E FY22E FY23E FY24E FY24E<	CMP TP M Cap Sales growth (%) EBITDA Margins (%) P/E(x) (₹) Rating (₹ Cr) FY22E FY23E FY24E FY22E FY23E FY24E FY24E<	CMP TP M Cap Sales growth (%) EBITDA Margins (%) P/E(x) (₹) Rating (₹ Cr) FY22E FY23E FY24E FY23E FY24E FY22E FY24E FY24E	CMP TP M Cap Sales growth (%) EBITDA Margins (%) P/E(x) P/E(x) (₹) Rating (₹ Cr) FY22E FY23E FY24E FY24E	CMP TP M Cap Sales growth (%) EBITDA Margins (%) P/E(x) RoE (%) (₹) Rating (₹ Cr) FY22E FY23E FY24E FY23E FY24E FY23E FY24E FY23E FY24E FY23E FY24E FY23E FY24E FY23E FY23E FY24E FY24	CMP TP M Cap Sales growth (%) EBITDA Margins (%) P/E(x) FRoE (%) (₹) Rating (₹ Cr) FY22E FY23E FY24E FY24E FY23E FY24E FY2	CMP TP M Cap Sales growth (%) EBITDA Margins (%) P/E(x) RoE (%) FV22E FY24E FY22E FY24E FY24E	CMP TP M Cap Sales growth (%) EBITDA Margins (%) P/E(x) RoE (%) RoE (%) RoCE (%) (₹) Rating (₹ Cr) FY22E FY23E FY24E FY22E FY24E FY24E FY22E FY24E FY24E

Source: Company, ICICI Direct Research

VBL witnessed 49.3% sales growth led by 40.9% volume growth in CY22 mainly on account of aggressive distribution expansion and significant improvement in mobility after two years of Covid-19 related disruption. Further, new product launched in last two years like 'Sting' & 'Dairy based beverages' has seen a robust growth in last one year. The company also remain relatively insulated with commodity inflation given it pro-actively procured 'PET resin' before the season. Operating leverage helped in expanding margins in CY22. The company is continuing its expansion spree in relatively weak markets like Rajasthan, Madhya Pradesh, UP & Bihar. Though we remain positive on growth prospects, it would be difficult to grow for the company at a very high pace on such a huge base in CY23. We remain positive on the company from a long-term perspective. We maintain our HOLD rating with a revised target price of ₹ 1340 (earlier:₹ 1235).

Exhibit 2: Variance Ar	alysis					
Particulars (₹ crore)	Q4CY22	Q4CY21	YoY (%)	Q3CY22	QoQ (%)	Comments
Net Sales	2,214.2	1,734.3	27.7	3,176.6	-30.3	Net sales witnessed growth of 27.7% led by 17.8% volume growth & strong realisation growth due to change in product mix
Raw Material Expenses	967.8	773.8	25.1	1,471.3	-34.2	Gross margins improved by 91 bps with stabalisation of RM prices & better product mix
Employee Expenses	319.9	259.8	23.1	311.2	2.8	
Other operating Expenses	619.0	493.1	25.5	695.1	-11.0	
EBITDA	307.5	207.6	48.1	699.0	-56.0	
EBITDA Margin (%)	13.9	12.0	192 bps	22.0	-812 bps	Operating margin improved by 192 bps largely due to gross margin expansion & operating leverage
Depreciation	179.7	129.3	39.0	153.1	17.3	Higher depreciation provising due to commissioning of new capacities
Interest	47.5	37.3	27.3	45.3	4.9	Increase in interest cost due to higher debt levels
Other Income	9.2	0.9	982.6	10.6	-12.9	
PBT	89.6	41.9	114.1	511.2	-82.5	
Exceptional Items	0.0	0.0		0.0		
Tax Outgo	8.1	9.3	-12.8	115.7	-93.0	
РАТ	81.5	32.6	150.2	395.5	-79.4	Net profit growth was led by robust operating profit growth & dip in tax rate after switching to new tax regime
Adj. PAT	81.5	32.6	150.2	395.5	-79.4	

Source: Company, ICICI Direct Research

		CY23E			CY24E		
(₹ Crore)	Old	New	% Change	Old	New	% Change	
Net Sales	14,461.3	14,558.6	0.7	16,156.5	16,263.8	0.7	We largely maintain our sales estimate
EBITDA	3,090.4	3,105.3	0.5	3,474.5	3,478.2	0.1	
EBITDA Margin(%)	21.4	21.3	-4 bps	21.5	21.4	-12 bps	
							We raise our interest cost estimate given the
PAT	1,739.3	1,692.2	-2.7	2,007.8	1,946.5	-3.1	company continues to maintain more than ₹ 3000 crore of debt
EPS (₹)	26.8	26.1	-2.8	30.9	30.0	-3.0	


Source: ICICI Direct Research

Exhibit 4: Assumptions									
			Current					ier	
Particulars (in million cases)	CY19	CY20	CY21	CY22	CY23E	CY24E	CY23E	CY24E	Comments
Carbonated Products	347.0	309.0	399.8	562.0	618.2	673.8	609.2	664.0	
Non Carbonated drinks	33.0	26.0	36.1	57.0	63.8	71.5	64.8	72.5	We slightly change our volume estimates
Water	111.0	90.0	132.3	182.0	205.7	226.2	207.8	228.6	

Source: ICICI Direct Research

Key Metrics

Exhibit 5: Revenue growth <u>trend (₹ crore)</u>



Source: Company, ICICI Direct Research


Exhibit 7: Raw material to sales & EBITDA margins (%)



Raw material as % of sales _____ EBITDA margin (%)

Source: Company, ICICI Direct Research

Exhibit 9: Robust earnings growth in last five years (₹ crore)




Source: Company, ICICI Direct Research

	Sales	Growth	EPS	Growth	PE	EV/EBITDA	RoNW	RoCE
	(₹ cr)	(%)	(₹)	(%)	(x)	(x)	(%)	(%)
CY21	8823.2	36.8	17.2	106.1	70.9	49.3	18.3	17.1
CY22	13173.1	49.3	23.9	38.5	51.2	29.7	30.4	23.8
CY23E	14558.6	10.5	26.1	9.2	46.9	26.1	26.6	27.2
CY24E	16263.8	11.7	30.0	15.0	40.7	23.0	25.5	30.6


Source: Company, ICICI Direct Research

ICICI Securities | Retail Research

Exhibit 6: Volume recovery to drive growth




Source: Company, ICICI Direct Research



Source: Company, ICICI Direct Research

Exhibit 10: Return ratio trend (%)



Source: Company, ICICI Direct Research

Financial Summary

Exhibit 12: Profit and los	ss stateme	nt		₹ crore
	CY21	CY22	CY23E	CY24E
Total operating Income	8823.2	13173.1	14558.6	16263.8
Growth (%)	36.8	49.3	10.5	11.7
Raw Material Expenses	4034.7	6261.2	6586.0	7357.2
Employee Expenses	1007.7	1216.6	1412.2	1610.1
Other expenses	2126.2	2907.2	3455.2	3818.3
Total Operating Expenditure	7168.6	10385.0	11453.3	12785.6
EBITDA	1,654.6	2,788.1	3,105.3	3,478.2
Growth (%)	37.7	68.5	11.4	12.0
Depreciation	531.3	617.2	774.0	824.0
Interest	184.7	186.1	204.5	201.8
Other Income	67.9	38.8	42.7	43.2
PBT	1006.6	2023.6	2169.5	2495.5
Total Tax	260.6	473.5	477.3	549.0
Minority interest	0.0	0.0	0.0	0.0
Profit from Associates	0.0	0.0	0.0	0.0
PAT	746.1	1,550.1	1,692.2	1,946.5
Growth (%)	106.1	107.8	9.2	15.0
EPS (₹)	17.2	23.9	26.1	30.0

Exhibit 13: Cash flow staten	nent		ŧ	₹ crore
(Year-end March)	CY21	CY22	CY23E	CY24E
Profit After Tax	1,067.4	1,835.8	1,896.7	2,148.3
Add: Depreciation	531.3	583.1	774.0	824.0
(Inc)/dec in Current Assets	-596.8	-1,005.9	-460.2	-599.9
Inc/(dec) in CL and Provisions	328.1	420.7	1,419.6	623.8
CF from operating activities	1,231.4	1,790.0	3,630.1	2,996.2
(Inc)/dec in Investments	0.0	0.0	0.0	0.0
(Inc)/dec in LT loans & advances	0.0	0.0	0.0	1.0
(Inc)/dec in Fixed Assets	-815.4	-1,749.9	-1,028.9	-878.9
Others	-87.7	45.3	0.0	0.0
CF from investing activities	-1,010.6	-1,704.6	-1,028.9	-878.9
Issue/(Buy back) of Equity	0.0	0.0	0.0	0.0
Inc/(dec) in loan funds	109.7	339.6	-1,700.0	-1,200.0
Dividend paid & dividend tax	-108.3	-162.4	-423.1	-681.3
Others	-179.1	-171.7	-204.5	-201.8
CF from financing activities	-177.7	-17.9	-2,579.0	-2,054.7
Net Cash flow	43.1	67.5	22.2	62.6
Opening Cash	104.6	150.8	154.3	176.6
Other Bank balance	185.9	185.9	185.9	185.9
Closing Cash	150.8	154.3	176.6	239.2

Source: Company, ICICI Direct Research

Exhibit 14: Balance Shee	t			₹ crore
(Year-end March)	CY21	CY22	CY23E	CY24E
Liabilities				
Equity Capital	433.0	649.5	649.5	649.5
Reserve and Surplus	3646.9	4452.8	5722.0	6987.2
Total Shareholders funds	4079.9	5102.4	6371.5	7636.8
LT Borrowings & Provisions	1813.3	1727.0	1227.0	577.0
Deferred Tax Liability	311.1	336.8	353.7	371.4
Total Liabilities	6561.6	7649.5	8167.2	8810.8
Assets				
Gross Block	8,974.6	10,220.9	11,727.5	12,677.5
Less: Acc Depreciation	3,246.6	3,863.8	4,637.8	5,461.9
Net Block	5,728.0	6,357.1	7,089.7	7,215.7
Capital WIP	496.6	606.6	150.0	50.0
Net Intangible Assets	558.6	550.9	578.5	607.4
Non-current Investments	0.8	0.0	0.0	0.0
Goodwill	24.2	24.2	24.2	24.2
Current Assets				
Inventory	1,448.1	1,993.9	2,305.1	2,710.6
Debtors	221.2	299.3	364.0	451.8
Loans and Advances	9.5	0.0	20.2	22.6
Other Current Assets	301.9	427.8	525.7	587.3
Cash	150.8	154.3	176.6	239.2
Deferred Tax Assests	2.4	0.0	0.0	0.0
Current Liabilities				
Creditors	711.8	824.3	889.7	993.9
Provisions	49.7	29.2	80.9	90.4
Short term debt & other CL	2,244.8	3,039.7	3,217.8	3,177.9
Application of Funds	6,561.6	7,649.5	8,167.2	8,810.8

Source: Company, ICICI Direct Research

Source: Company, ICICI Direct Research

(Year-end March)	CY21	CY22	CY23E	CY24E
Per share data (₹)				
EPS	17.2	23.9	26.1	30.0
Cash EPS	29.5	33.4	38.0	42.7
BV	94.2	78.6	98.1	117.6
DPS	2.5	6.0	6.5	10.
Cash Per Share	75.0	59.5	71.4	84.1
Operating Ratios (%)				
EBITDA Margin	18.8	21.2	21.3	21.4
PBT / Total Operating income	11.4	15.4	14.9	15.3
PAT Margin	8.5	11.8	11.6	12.0
Inventory days	60	55	58	61
Debtor days	9	8	9	10
Creditor days	29	23	22	22
Return Ratios (%)				
RoE	18.3	30.4	26.6	25.5
RoCE	17.1	23.8	27.2	30.6
Valuation Ratios (x)				
P/E	70.9	51.2	46.9	40.7
ev / Ebitda	49.3	29.7	26.1	23.0
EV / Net Sales	9.2	6.3	5.6	4.9
Market Cap / Sales	9.0	6.0	5.4	4.9
Price to Book Value	13.0	15.5	12.4	10.4
Solvency Ratios				
Debt/EBITDA	1.5	1.3	0.6	0.2
Debt / Equity	0.6	0.7	0.3	0.1
Current Ratio	0.7	1.2	0.8	0.8
Quick Ratio	0.1	0.2	0.1	0.1

Exhibit 16: ICICI Direct coverage universe (FMCG)

	CMP TP			M Cap EPS (₹)				P/E (x) Price/Sales (x)				(x)	RoCE (%)			RoE (%)			
	(₹)	(र)	Rating	(₹ Cr)	FY22	FY23E	FY24E	FY22	FY23E	FY24E	FY22	FY23E	FY24E	FY22	FY23E	FY24E	FY22	FY23E	FY24E
Colgate (COLPAL)	1,457	1,440	Hold	39,473	39.6	37.7	40.3	36.8	38.6	36.2	7.8	7.6	7.1	77.8	79.3	84.2	62.2	60.4	64.1
Dabur India (DABIND)	545	700	Buy	97,880	9.9	10.3	12.0	55.3	53.1	45.3	9.0	8.5	7.7	24.9	23.9	26.1	20.8	20.5	22.2
Hindustan Unilever (HINLEV)	2,638	2,800	Hold	6,04,971	37.5	42.0	46.7	70.3	62.7	56.5	12.0	10.3	9.4	20.2	22.9	25.6	18.1	20.3	22.4
ITC Limited (ITC)	383	450	Buy	4,67,841	12.4	14.7	16.0	30.9	26.1	23.9	7.9	6.8	6.2	31.4	36.0	37.5	24.5	27.7	28.7
Jyothy Lab (JYOLAB)	213	215	Hold	7,485	4.3	6.7	7.8	50.2	32.0	27.4	3.5	3.1	2.8	18.7	27.5	31.4	16.6	24.2	27.0
Marico (MARLIM)	505	555	Hold	63,710	9.7	10.3	11.1	51.9	49.0	45.4	6.7	6.5	6.0	41.2	44.0	46.2	37.5	38.5	40.6
Nestle (NESIND)	19,022	22,400	Hold	1,90,912	222.4	255.8	301.1	85.5	74.4	63.2	13.0	11.4	10.3	58.7	57.1	63.0	111.3	103.6	110.3
Patanjali Foods (RUCSOY)	938	1,750	Buy	50,721	27.3	30.9	43.5	34.4	30.3	21.6	2.1	1.7	1.5	13.2	15.6	17.3	13.1	11.3	14.2
Tata Consumer Products (TAT	730	950	Buy	66,879	11.0	14.3	15.8	66.2	50.9	46.2	5.4	4.9	4.4	8.4	8.8	10.3	7.0	7.6	9.0
Varun Beverage (VARBEV)	1,222	1,340	Hold	79,300	17.2	23.9	26.1	70.9	51.2	46.9	9.0	6.0	5.4	17.1	23.8	27.2	18.3	30.4	26.6
VST Industries (VSTIND)	3,010	3,300	Hold	4,807	207.4	214.1	229.4	14.5	14.1	13.1	4.1	3.6	3.4	39.2	41.8	49.1	30.0	31.9	36.9
Zydus Wellness (ZYDWEL)	1,465	2,000	Buy	8,979	48.5	55.0	67.4	30.2	26.6	21.7	4.5	4.0	3.6	6.1	6.8	8.1	6.4	7.1	8.3
Zydus Weilliess (ZTDWEL)			buy	0,979	40.0	55.0	07.4	30.Z	20.0	21.7	4.0	4.0	3.0	0.1	0.0	0.1	0.4	7.1	

Source: Bloomberg, ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according -to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15% Hold: -5% to 15%; Reduce: -15% to -5%; Sell: <-15%



Pankaj Pandey

Head – Research

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com pankaj.pandey@icicisecurities.com

ANALYST CERTIFICATION

I/We, Sanjay Manyal MBA (FINANCE) Research Analyst, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or comanaging public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.